Skip to main content

Kazimi A J's Form 4 filing

Cumberland Pharmaceuticals Inc (CPIX) ยท filed Sep 10, 2021

Accession no.
0001209191-21-055496
Filed
Sep 10, 2021
Trade date
Apr 16-May 27, 2021
Filing delay
147 daysLate
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 30 non-derivative transactions. Open-market purchases total $1.29K. It was filed 147 days after the trade, past the 2-business-day deadline.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Kazimi A JCIK 0001075050Director, Officer (Chairman and CEO), 10% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Apr 16, 2021Common StockPPurchaseAcquired+15$3.03+$45.455,767,734Direct
Apr 19, 2021Common StockPPurchaseAcquired+15$3.04+$45.65,767,749Direct
Apr 20, 2021Common StockPPurchaseAcquired+15$3.02+$45.35,767,764Direct
Apr 21, 2021Common StockPPurchaseAcquired+15$2.97+$44.555,767,779Direct
Apr 22, 2021Common StockPPurchaseAcquired+15$2.96+$44.45,767,794Direct
Apr 23, 2021Common StockPPurchaseAcquired+15$2.99+$44.855,767,809Direct
Apr 26, 2021Common StockPPurchaseAcquired+15$2.97+$44.555,767,824Direct
Apr 27, 2021Common StockPPurchaseAcquired+15$2.94+$44.15,767,839Direct
Apr 28, 2021Common StockPPurchaseAcquired+15$2.94+$44.15,767,854Direct
Apr 29, 2021Common StockPPurchaseAcquired+15$2.89+$43.355,767,869Direct
Apr 30, 2021Common StockPPurchaseAcquired+15$2.78+$41.75,767,884Direct
May 3, 2021Common StockPPurchaseAcquired+15$2.66+$39.95,767,899Direct
May 4, 2021Common StockPPurchaseAcquired+15$2.66+$39.95,767,914Direct
May 5, 2021Common StockPPurchaseAcquired+15$2.73+$40.955,767,929Direct
May 6, 2021Common StockPPurchaseAcquired+15$2.74+$41.15,767,944Direct
May 7, 2021Common StockPPurchaseAcquired+15$2.73+$40.955,767,959Direct
May 10, 2021Common StockPPurchaseAcquired+15$2.71+$40.655,767,974Direct
May 11, 2021Common StockPPurchaseAcquired+15$2.68+$40.25,767,989Direct
May 12, 2021Common StockPPurchaseAcquired+15$2.86+$42.95,768,004Direct
May 13, 2021Common StockPPurchaseAcquired+15$2.88+$43.25,768,019Direct
May 14, 2021Common StockPPurchaseAcquired+15$2.81+$42.155,768,034Direct
May 17, 2021Common StockPPurchaseAcquired+15$2.84+$42.65,768,049Direct
May 18, 2021Common StockPPurchaseAcquired+15$2.89+$43.355,768,064Direct
May 19, 2021Common StockPPurchaseAcquired+15$2.83+$42.455,768,079Direct
May 20, 2021Common StockPPurchaseAcquired+15$2.94+$44.15,768,094Direct
May 21, 2021Common StockPPurchaseAcquired+15$3.06+$45.95,768,109Direct
May 24, 2021Common StockPPurchaseAcquired+15$3.05+$45.755,768,124Direct
May 25, 2021Common StockPPurchaseAcquired+15$2.91+$43.655,768,139Direct
May 26, 2021Common StockPPurchaseAcquired+15$2.85+$42.755,768,154Direct
May 27, 2021Common StockPPurchaseAcquired+15$2.94+$44.15,768,169Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

No transaction price on this filing refers to a footnote.

Read the full filing on SEC EDGAR (opens in a new tab)